Clinical Trial Update: Phase II Trial Of Gemcitabine Plus Nab-Paclitaxel +/- OGX-427 In Patients With Metastatic Pancreatic Cancer [Phase 2]

View source ↗

Summary

A Phase II trial evaluating gemcitabine plus nab-paclitaxel with or without OGX-427 (apatorsen) in metastatic pancreatic cancer has completed enrollment and pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Cancer

Drugs mentioned

• Gemcitabine (Gemcitabine)
• Nab-paclitaxel (paclitaxel protein-bound)
• OGX-427 (apatorsen)

Snippet

Sponsor: SCRI Development Innovations, LLC | Conditions: Pancreatic Cancer | Phase 2 | Status: COMPLETED | Results posted: 2017-05-16